ELISA Kit for Placenta Growth Factor (PLGF)
PlGF2; PGF; PGFL; Placental Growth Factor-Like; Vascular Endothelial Growth Factor-Related Protein
- Product No.SEA114Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample TypeSerum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3h
- Detection Range15.6-1,000pg/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 6.5pg/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
For more details, please contact local distributors! US$ 498
For more details, please contact local distributors! US$ 2241
For more details, please contact local distributors! US$ 4233
For more details, please contact local distributors! US$ 34860
For more details, please contact local distributors!
This assay has high sensitivity and excellent specificity for detection of Placenta Growth Factor (PLGF).
No significant cross-reactivity or interference between Placenta Growth Factor (PLGF) and analogues was observed.
Matrices listed below were spiked with certain level of recombinant Placenta Growth Factor (PLGF) and the recovery rates were calculated by comparing the measured value to the expected amount of Placenta Growth Factor (PLGF) in samples.
|Matrix||Recovery range (%)||Average(%)|
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Placenta Growth Factor (PLGF) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Placenta Growth Factor (PLGF) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Placenta Growth Factor (PLGF) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
|Pre-coated, ready to use 96-well strip plate||1||Plate sealer for 96 wells||4|
|Detection Reagent A||1×120µL||Assay Diluent A||1×12mL|
|Detection Reagent B||1×120µL||Assay Diluent B||1×12mL|
|TMB Substrate||1×9mL||Stop Solution||1×6mL|
|Wash Buffer (30 × concentrate)||1×20mL||Instruction manual||1|
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
|Microvascular Research||Mutant hypoxia inducible factor-1α improves angiogenesis and tissue perfusion in ischemic rabbit skeletal muscle PubMed: 20937289|
|Oncogene||Elevated PLGF contributes to small-cell lung cancer brain metastasis PubMed: 22797069|
|?eLife||Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1 PubMed: PMC3687373|
|International Journal of Nanomedicine||Sustained dual release of placental growth factor-2 and bone morphogenic protein-2 from heparin-based nanocomplexes for direct osteogenesis Pubmed:27042064|
|The Journal of Maternal-Fetal & Neonatal Medicine||Serum angiogenic profile in abnormal placentation Pubmed:26863111|
|Fertility and Sterility||Administration of atosiban in patients with endometriosis undergoing frozenâthawed embryo transfer: a prospective, randomized study Pubmed:27143518|
|Basic & Clinical Pharmacology & Toxicology||Placental Growth Factor Triggers Epithelial-to-Mesenchymal Transition-like Changes in Rat Type II Alveolar Epithelial Cells: Activation of Nuclear Factor κB Signalling Pathway doi:10.1111|
|Life Sci.||Placenta growth factor contributes to cell apoptosis and epithelial-to-mesenchymal transition in the hyperoxia-induced acute lung injury Pubmed:27211521|
|Int Immunopharmacol||Knockdown of placental growth factor (PLGF) mitigates hyperoxia-induced acute lung injury in neonatal rats: Suppressive effects on NFκB signaling pathway Pubmed:27280587|
|Catalog No.||Related products for research use of Homo sapiens (Human) Organism species||Applications (RESEARCH USE ONLY!)|
|RPA114Hu01||Recombinant Placenta Growth Factor (PLGF)||Positive Control; Immunogen; SDS-PAGE; WB.|
|PAA114Hu01||Polyclonal Antibody to Placenta Growth Factor (PLGF)||WB; IHC; ICC; IP.|
|MAA114Hu22||Monoclonal Antibody to Placenta Growth Factor (PLGF)||WB; IHC; ICC; IP.|
|SEA114Hu||ELISA Kit for Placenta Growth Factor (PLGF)||Enzyme-linked immunosorbent assay for Antigen Detection.|